Provention bio reports first quarter 2022 financial results and provides business update

-teplizumab biologics license application (bla) resubmission accepted for review by fda and user fee goal date set for august 17, 2022- -company to host teplizumab commercial launch investor event on thursday, may 19, 2022- red bank, n.j. , may 5, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the first quarter ended march 31, 2022, and provided a business update.
PRVB Ratings Summary
PRVB Quant Ranking